Virios Therapeutics, Inc. (VIRI): Price and Financial Metrics
VIRI Price/Volume Stats
| Current price | $0.46 | 52-week high | $2.42 |
| Prev. close | $0.43 | 52-week low | $0.28 |
| Day low | $0.43 | Volume | 64,200 |
| Day high | $0.47 | Avg. volume | 346,759 |
| 50-day MA | $0.41 | Dividend yield | N/A |
| 200-day MA | $0.79 | Market Cap | 8.78M |
VIRI Stock Price Chart Interactive Chart >
Virios Therapeutics, Inc. (VIRI) Company Bio
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
Latest VIRI News From Around the Web
Below are the latest news stories about VIRIOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VIRI as an investment opportunity.
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call TranscriptVirios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript November 13, 2023 Virios Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.1. Operator: Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update. At this time, all participants have been placed on a listen-only mode. Please be advised […] |
VIRI: Provides Overview of Phase 3 Program in FibromyalgiaBy David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Overview of Phase 3 Program for IMC-1 in Fibromyalgia Virios Therapeutics, Inc. (NASDAQ:VIRI) is developing IMC-1 (combination of famciclovir and celecoxib) as a therapy for fibromyalgia (FM). The company previously reported results from the Phase 2b FORTRESS trial in September 2022. Topline results showed that the |
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the third quarter ended September 30, 2023. Key Highlights and Upcoming Milestones Having secured FDA guidance on our plan to progress IM |
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets. Management will also host a webcast and conference call on November |
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY. The live and archived webcast of the session may b |
VIRI Price Returns
| 1-mo | -4.90% |
| 3-mo | 12.20% |
| 6-mo | -0.88% |
| 1-year | -47.13% |
| 3-year | -91.74% |
| 5-year | N/A |
| YTD | -20.00% |
| 2023 | 143.64% |
| 2022 | -95.39% |
| 2021 | -31.89% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...